

RESULTS OF THE EXTRAORDINARY GENERAL MEETING

An extraordinary general meeting of Forward Pharma A/S (the “Company”) was held on 1 February 2017 at the Company’s offices, Østergade 24A, 1st floor, 1100 Copenhagen K, Denmark (the “Extraordinary General Meeting”). Nominally DKK 3,531,376 of the Company’s share capital and 35,313,760 votes, respectively (equal to 74.91% of the Company’s total share capital and votes, respectively), were represented at the Extraordinary General Meeting. The results of the Extraordinary General Meeting were as follows:

- (1) The proposal to approve (i) the Company’s entry into the Settlement and License Agreement with Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd. and the other parties thereto (the “License Agreement”) and the consummation of the transactions contemplated thereby and (ii) the Company’s entry into an addendum (the “Addendum”) to the patent transfer agreement dated 4 May 2010 between the Company and Aditech Pharma AG and the consummation of the transactions contemplated thereby, was approved by 35,313,760 votes in favour (representing 100% of the votes cast and the share capital represented at the extraordinary general meeting), 0 votes against and with 0 abstentions.
- (2) The proposal to authorize the non-disqualified members of the Board of Directors of the Company to negotiate and execute an indemnification agreement between the Company on the one hand and certain companies affiliated with Florian Schönharting that are party to the License Agreement and Florian Schönharting, in his individual capacity, on the other hand was approved by 35,313,760 votes in favour (representing 100% of the votes cast and the share capital represented at the extraordinary general meeting), 0 votes against and with 0 abstentions.
- (3) The proposal to authorize each of Karen Smith, Jan van de Winkel and Grant Lawrence to sign the License Agreement and the Addendum on behalf of the Company was approved by 35,313,760 votes in favour (representing 100% of the votes cast and the share capital represented at the extraordinary general meeting), 0 votes against and with 0 abstentions.